



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE

1st Edition

---

# CLSI M64™

## Implementation of Taxonomy Nomenclature Changes

CLSI M64 includes recommendations for implementing nomenclature changes for medically important bacteria and fungi that are identified and reported from clinical specimens, especially when testing for antimicrobial susceptibility.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

## Implementation of Taxonomy Nomenclature Changes

Erik Munson, PhD, D(ABMM)  
Shawn R. Lockhart, PhD, D(ABMM), F(AAM)  
Lynette Y. Berkeley, MLS(ASCP), PhD  
Romney M. Humphries, PhD, D(ABMM), FIDSA  
Kathryn Bernard, MSc, F(AAM), ARM(CCM)  
Claire R. Burbick, DVM, PhD, DACVM  
Rafael Canton, PhD  
Karen C. Carroll, MD

Victoria Girard, PhD  
Laura M. Koeth, BS, MLS(ASCP)  
Sara D. Lawhon, DVM, PhD, DACVM  
Stephanie L. Mitchell, PhD, D(ABMM)  
Elizabeth Palavecino, MD  
Robin Patel, MD  
David H. Pincus, MS, RM/SM(NRCM), SM(ASCP)  
Nathan P. Wiederhold, PharmD

### Abstract

Clinical and Laboratory Standards Institute M64—*Implementation of Taxonomy Nomenclature Changes* provides background and historic information related to the process of microbial taxon discovery, publication, and acceptance by recognized professional committees and societies. Additional nuances within these topics exist in the field of medical mycology. CLSI M64 reflects collaborative discussions from experts in the fields of medical bacteriology, medical mycology, veterinary diagnostic microbiology, antimicrobial susceptibility testing, and diagnostics manufacturing. Recommendations are provided for the implementation of novel and revised taxonomy in human and veterinary microbiology laboratories. A two- to three-year timeline is presented for laboratories to enact these changes; changes that may more profoundly affect patient care can be acted upon more expeditiously. Communication with clinical and public health stakeholders is imperative to the successful implementation of taxonomic changes.

Clinical and Laboratory Standards Institute (CLSI). *Implementation of Taxonomy Nomenclature Changes*. 1st ed. CLSI guideline M64 (ISBN 978-1-68440-264-9 [Print]; ISBN 978-1-68440-655-6 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2024.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, and users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@clsi.org](mailto:customerservice@clsi.org) **W:** [www.clsi.org](http://www.clsi.org)

Copyright ©2024 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, or other product or material requires express written consent from CLSI.

All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

To read CLSI's full Copyright Policy, please visit our website at <https://clsi.org/terms-of-use/>.

## Suggested Citation

CLSI. *Implementation of Taxonomy Nomenclature Changes*. 1st ed. CLSI guideline M64. Clinical and Laboratory Standards Institute; 2024.

CLSI M64-ED1

ISBN 978-1-558-264-9 (Print)

ISBN 978-1-68440-265-6 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 44, Number 30

## Committee Membership

### Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council/>

### Document Development Committee on Taxonomy Changes

<b>Erik Munson, PhD, D(ABMM)</b> <b>Chairholder</b> <b>Marquette University</b> <b>USA</b>	Claire R. Burbick, DVM, PhD, DACVM Washington State University USA	Sara D. Lawhon, DVM, PhD, DACVM Texas A & M University USA
<b>Shawn R. Lockhart, PhD, D(ABMM), F(AAM)</b> <b>Vice-Chairholder</b> <b>Centers for Disease Control and Prevention</b> <b>USA</b>	Rafael Canton, PhD European Committee on Antimicrobial Susceptibility Testing (EUCAST) Spain	Stephanie L. Mitchell, PhD, D(ABMM) Cepheid USA
<b>Romney M. Humphries, PhD, D(ABMM), FIDSA</b> <b>Committee Secretary</b> <b>Vanderbilt University Medical Center</b> <b>USA</b>	Karen C. Carroll, MD Johns Hopkins University School of Medicine USA	Elizabeth Palavecino, MD Wake Forest Baptist Medical Center USA
Lynette Y. Berkeley, MLS(ASCP), PhD FDA Center for Drug Evaluation and Research USA	Victoria Girard, PhD bioMérieux France	Robin Patel, MD Mayo Clinic USA
	Laure M. Smith, BS, MLS(ASCP) Laboratory Specialists, Inc. USA	Nathan P. Wiederhold, PharmD University of Texas Health Science Center at San Antonio USA

### Expert Panel on Microbiology

Expert panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels/>

## Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Taxonomy Changes gratefully acknowledge the following volunteers for their important contributions to the development of CLSI M64:

Kevin Alby, PhD, D(ABMM)  
UNC Hospital  
USA

German Esparza, MSc  
Proasecal SAS Colombia  
Colombia

David H. Pincus, MS, RM/SM (NRCM),  
SM(ASCP)  
USA

Stella Antonara, PhD, D(ABMM)  
American Society for Microbiology  
USA

Mark J. Lee, PhD, D(ABMM), M(ASCP)  
Duke University Health System  
USA

Stefan Schwarz, DVM  
Freie Universitat Berlin  
Germany

Kathryn Bernard, MSc, F(AAM),  
ARM(CCM)  
Canada

Niki Litchfield, MS  
Becton Dickinson  
USA

Priyanka Uprety, MSPH, PhD,  
D(ABMM)  
Becton Dickinson  
USA

April M. Bobenchik, PhD, D(ABMM)  
Penn State Health, Milton S. Hershey  
Medical Center  
USA

Kiyofumi Ohkusu, PhD  
Tokyo Medical University  
Japan

Collette W. Orr  
Becton Dickinson  
USA

# Contents

Abstract .....	i
Committee Membership .....	iii
Foreword .....	vii
<b>Chapter 1: Introduction .....</b>	<b>1</b>
1.1 Scope .....	1
1.2 Standard Precautions .....	2
1.3 Terminology .....	2
<b>Chapter 2: Taxonomy Revisions Path of Workflow .....</b>	<b>5</b>
<b>Chapter 3: Validation of Taxonomic Nomenclature .....</b>	<b>9</b>
3.1 Historical Perspective .....	10
3.2 Identification and Description of New Taxa .....	11
3.3 Valid Recognition and Acceptance of New Taxa .....	15
3.4 Caveats and Limitations to Assignment of New Taxa .....	17
<b>Chapter 4: Significance of Bacterial Nomenclature Changes for Medical and Veterinary Microbiology Laboratories .....</b>	<b>21</b>
4.1 Importance of Adopting Nomenclature Changes .....	22
4.2 Resources for Becoming Informed of Nomenclature Changes and Novel Taxa .....	27
<b>Chapter 5: Recommendations for Implementation of Nomenclature Changes for Fungi Causing Disease in Animals and Humans .....</b>	<b>29</b>
5.1 Identification of Yeasts in the Medical Laboratory .....	30
5.2 Brief Overview of Reasons for Fungal Taxonomy Revision .....	31
5.3 Sources for Changes in Fungal Nomenclature and How Changes Become Validated .....	35
5.4 Significance of Identification for Fungal Species in Veterinary Medicine .....	36
5.5 Effect of Nomenclature Changes on Antifungal Susceptibility Testing .....	36
5.6 Validation .....	38
<b>Chapter 6: Recommendations for Implementation of Nomenclature Changes for Bacteria and Fungi Causing Disease in Animals and Humans .....</b>	<b>39</b>
6.1 General Recommendations for Adopting Nomenclature Changes .....	40
6.2 Timing of Adopting Nomenclature Changes .....	40
6.3 Communication of Nomenclature Changes .....	49

# Contents (Continued)

.....

**Chapter 7: Quality System Essentials** ..... 53

    7.1 Organization and Leadership ..... 54

    7.2 Personnel Management ..... 54

    7.3 Equipment Management ..... 55

    7.4 Process Management ..... 55

    7.5 Documents and Records Management ..... 55

    7.6 Information Management ..... 55

    7.7 Nonconforming Event Management ..... 55

    7.8 Assessments ..... 55

    7.9 Continual Improvement ..... 55

**Chapter 8: Conclusion** ..... 57

**Chapter 9: Supplemental Information** ..... 59

**References** ..... 60

**Appendix A.** Example Microbiology Laboratory Report With Commentary Describing Effect of Potential Therapeutic Options as a Result of Taxonomic Revision ..... 74

**Appendix B.** Example Microbiology Laboratory Report With Commentary Describing New Taxon Relevance ..... 75

**Appendix C.** Example Mycology Laboratory Report With Commentary Describing Teleomorph Nomenclature Revision ..... 76

**The Quality Management System Approach** ..... 78

.....

## Foreword

Advancements in molecular, proteomic, and phylogenetic technology in both the clinical and research setting have resulted in a plethora of novel bacterial and fungal taxa, as well as revisions to the nomenclature of currently existing microbes. CLSI M64 has been developed to provide laboratorians with practical guidance on how to assimilate novel and revised taxonomy into the medical and veterinary microbiology laboratories. To provide the medical laboratorian a more complete understanding of this topic, CLSI M64 provides several foundational summaries, including:

- A brief history of microbial systematics
- Contemporary attempts at nomenclature standardization
- General processes (including phenotypic and genotypic investigations) involved in the discovery, initial characterization, and effective publication of novel taxa
- Analogous processes that result in taxonomic revisions
- Criteria for official acceptance of novel and/or revised taxonomy
- Effect of the ever-changing field of microbial taxonomy on other scientific and medical disciplines

New taxonomy often comes with controversies, including determining the clinical relevance of these revised or novel taxa. CLSI M64 elaborates on these issues in an unbiased manner, using the expertise of scientists in the fields of infectious diseases, infection control and prevention, medical microbiology, medical mycology, veterinary diagnostic microbiology, antimicrobial and fungal susceptibility testing and pharmacology, and diagnostics manufacturing. While the bacterial taxonomy field has an ultimate adjudication authority, the medical mycology field has no authoritative organization for taxonomy. The ultimate deliverables within CLSI M64 are two sets of recommendations for implementing bacterial and fungal nomenclature revisions in medical and veterinary microbiology laboratories, along with a rationale for these recommendations. Final implementation may necessitate raising awareness of taxonomic revisions, performing various validation procedures, interacting with commercial diagnostics manufacturers, and communicating with important stakeholders.

**NOTE:** The content of CLSI M64 is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

### KEY WORDS

anamorph

*International Code of Nomenclature of Prokaryotes*

International Committee on Systematics of Prokaryotes

novel species taxonomy

systematics

taxonomy revision

teleomorph

Validation Lists

Currently in preview, click buy full version

# Chapter ①

## Introduction

# Implementation of Taxonomy Nomenclature Changes

---

## 1 Introduction

### 1.1 Scope

CLSI M64 focuses on nomenclature changes for medically important bacteria and fungi that are included in CLSI documents, especially CLSI antimicrobial susceptibility testing (AST) standards and guidelines, as well as documents that cover molecular techniques that apply to bacteria and fungi. Veterinary pathogens are also included. CLSI M64 is intended for use by human and veterinary microbiology laboratory personnel, as well as primary and consulting care clinicians, pharmacists, and infection preventionists.

CLSI M64 discusses how and why changes to the nomenclature are made. It includes guidelines for assessing the effect of a nomenclature change on clinical care (eg, factors to consider). It includes tables with examples of changes proposed in the literature, a brief summary of why the changes are proposed, recommendations for reporting in a medical laboratory, and statements on the clinical effects of the recommendations. CLSI M64 does not include nomenclature changes for parasites and viruses causing disease in humans and animals.

### 1.2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.<sup>1</sup> For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI M29.<sup>2</sup>

### 1.3 Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization whenever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in different countries and regions and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. CLSI recognizes its important role in these efforts, and its consensus process focuses on harmonization of terms to facilitate the global application of standards and guidelines. Table 1 is provided to clarify the intended interpretations of common terms.